Objectives: In controlled trials of analgesics for the treatment of neuropathic pain, the primary outcome variable is most often a measure of global pain intensity. However, because neuropathic pain is associated with a variety of pain sensations, the effects of analgesic treatments on different sensations could go undetected if specific pain qualities are not assessed. This study sought to evaluate the utility of assessing the multiple components of neuropathic pain in an analgesic clinical trial.
N europathic pain is pain that is initiated or caused by a primary lesion or dysfunction in the nervous system. 1 Prevalence estimates suggest that approximately 1.5% of Americans suffer from neuropathic pain. 2 Neuropathic pain is very difficult to treat, and no single intervention or treatment has been shown to be effective for all patients. [3] [4] [5] [6] Diabetic peripheral neuropathy is one of the leading causes of neuropathic pain. Approximately 0.6% of the U.S. population suffers from diabetic neuropathy. 2 Of these, one study reported that less than 10% of patients in a clinical setting experienced pain, 7 although in another study pain was reported by 32% of a sample of non-insulin-dependent patients with diabetes. 8 The pain that is associated with this condition is often described as superficial, predominantly burning, shooting/electric-like, tingling, and aching and most often appears to affect the feet and hands. 5 Controlled clinical trials of analgesic efficacy in patients with neuropathic pain usually (and appropriately) rely on ratings of global pain intensity as the primary outcome measure, [9] [10] [11] [12] [13] [14] although they often assess other outcome domains, such as psychological functioning, 9 disability, 9, 11, 13 and composite measures of pain experience such as the McGill Pain Questionnaire (original or short form) 9, 13, 15 as secondary outcome measures. However, measures of specific pain qualities, such as perceived temperature (hot, cold), depth (deep, surface), or specific sensations (eg, sharp, dull, itchy) are rarely included in clinical trials (see 14 for a rare exception). Whereas pain intensity is a reasonable primary outcome dimension in analgesic trials, excluding measures of specific pain qualities has potential drawbacks. To the extent that global pain intensity ratings represent an estimate of average pain (across all pain sensations), it is possible that a treatment could have a greater effect on one (or more) specific pain sensations than it does on global pain intensity. 16 Thus, if only global measures of pain experience are used in analgesic trials, the effects of treatments on specific pain sensations could go undetected.
Neuropathic pain conditions are known to have diverse etiologies, each of which can produce a different pain sensation or cluster of sensations. Different therapies may also produce different effects on each specific pain sensation type. 3, 4, 6 Hence, it is conceivable that a different pattern of pretreatment or baseline pain qualities would be associated with different neuropathic pain conditions, or that treatments with proven efficacy in reducing neuropathic pain will produce different effects across a variety of pain sensations. A measure of multiple pain qualities is needed to determine if patients with neuropathic pain from different diagnostic groups report different profiles of pain sensations, and if different analgesics have specific effects on specific pain qualities.
Galer and Jensen 16 developed the Neuropathic Pain Scale (NPS) to help address these questions. The NPS assesses two global pain domains (pain intensity and unpleasantness), six pain qualities (sharp, hot, dull, cold, sensitive, and itchy pain), and two pain locations (deep and surface pain). The 10 NPS items show weak associations with one another (supporting their discriminant validity), are able to distinguish patients from different diagnostic groups, and show different levels of responsivity to pain treatment, supporting the potential of the NPS items to detect treatment effects not detected by pain intensity ratings alone. 16 However, the validity of the NPS for detecting changes in pain in the context of a randomized clinical trial has not yet been evaluated. The purpose of the current study was to fill this gap. The data for this study were obtained from a randomized controlled trial of an opioid (controlled-release oxycodone) in persons with painful diabetic neuropathy, details of which have been previously published. 17 This study showed that the study medication was effective for reducing pain intensity, relative to placebo, from day 3 until the end of the study trial (day 42), as measured by daily ratings of average pain intensity on 0-to-10 numeric scales. The primary objectives of this reanalysis were to determine whether the NPS items are sensitive to the effects of time and opioid treatment in a clinical trial that used an analgesic known to affect pain, and, if sensitive to treatment, to describe the pattern of changes in pain sensations caused by the opioid used in this sample of persons with painful diabetic neuropathy.
Given that the primary analyses showed pre-to posttreatment decreases in pain intensity in both treatment groups, with patients in the opioid treatment condition showing greater decreases than patients in the placebo condition, 17 we hypothesized that participants in both conditions would report decreases in neuropathic pain sensations as assessed by the NPS, and that participants in the opioid condition would report greater reductions in some specific pain sensations than participants in the placebo condition.
Specific hypotheses concerning the effects of the opioid treatment on the different pain sensations assessed by the NPS were based in part on the findings from previous studies that examined the effects of a mixed analgesic in patients with painful neuropathy 18, 19 and two studies that used an opioid treatment (oxycodone) in patients with neuropathic pain 14, 20 In each of these studies, the analgesics reduced allodynia-the perception of severe pain after a seemingly innocuous stimulus. We therefore hypothesized that the opioid used in the present study would have positive effects on sensitive and surface pain in patients with painful diabetic neuropathy compared with placebo. One of the studies found that oxycodone reduced ''brief '' pain (pain that is perceived as ''shock-like'' or ''lancinating'') in a sample of patients with painful diabetic neuropathy. Based on these findings, we anticipated that oxycodone would reduce ''sharp'' pain in the current study. Because pruritus is a common side effect of opioid treatment, it was further hypothesized that opioid treatment would increase itchy pain sensations relative to the placebo. Finally, based on the findings of the primary study, 17 we predicted that patients who received the opioid treatment would report greater reductions in global pain intensity and unpleasantness than patients who received the placebo. However, no specific hypotheses were made concerning the effects of the opioid treatment on hot, dull, cold, or deep pain because of the lack of previous research examining the effects of opioids on these pain sensations.
METHODS

Subjects
Subjects included 159 patients with type 1 or type 2 diabetes mellitus as defined by insulin dependence, dependence on oral hypoglycemic agents, or the World Health Organization criteria for diabetes. Detailed descriptive information about the subjects and the inclusion/exclusion criteria are described in the primary outcome paper from this study. 17 In brief, there were 82 subjects in the opioid group and 77 in the placebo group. Of the 159 subjects, 83 (52%) were male, 134 (84%) were white, and 106 (67%) were aged younger than 65 years, with a mean age of 58.9 years (range 27282 years). A total of 115 (72%) subjects completed the study-63 of 82 controlled-release (CR) oxycodone subjects (77%) and 52 of 77 placebo subjects (68%). Forty-four subjects (28%) discontinued for various reasons-12 due to ineffective treatment (1 CR oxycodone subject, 11 placebo subjects), 11 due to adverse events (7 and 4 subjects, respectively), 7 due to protocol violations (2 and 5 subjects, respectively), and 14 for other reasons (9 and 5 subjects, respectively).
Procedures
The study was conducted according to the Declaration of Helsinki and was approved by institutional review boards at each of the 15 sites in the United States. All subjects gave informed written consent. The study was conducted between June 1999 and June 2000.
The study was designed as a multicenter, randomized, double-blind comparison of CR oxycodone and placebo. There was an initial washout/screening phase of 3 to 7 days, during which subject eligibility was assessed and all opioid therapy was discontinued, followed by a 42-day, double-blind treatment period. A computer-generated randomization schedule with permuted blocks of size 4 was used to assign subjects to study treatment. Subjects received either CR oxycodone (OxyContin, Purdue Pharma, L.P., Stamford, CT) or an identical placebo tablet every 12 hours during the 6-week treatment period. Dosing began with one 10-mg tablet of CR oxycodone or placebo. If after 3 days on a stable dose, subjects did not achieve adequate pain control (defined as an average pain intensity of #4 on a scale of 0210), the dose could be increased every 3 days to a maximum dose of six tablets (60 mg CR oxycodone) every 12 hours.
Study Measures
Pain sensations were measured using the NPS. 16 The NPS was administered just before treatment and again at 2, 4, and 6 weeks of double-blind treatment. The NPS contains an introduction describing how people may experience pain sensations differently and how unpleasantness differs from intensity. The scale presents 10 domains of pain, including two items that assess global pain intensity and pain unpleasantness and eight items that assess the specific qualities or locations of neuropathic pain: sharp, hot, dull, cold, sensitive, itchy, deep, and surface. Subjects were asked to rate each quality of pain on a scale of 0 to 10, where 0 = no pain or not ______ [item] and 10 = the most ______ [item] sensation imaginable.
Statistical Analysis
Intent-to-treat analyses were performed using data from 159 subjects who received at least one dose of study medication. The effects of CR oxycodone on each of the 10 pain dimensions assessed by the NPS were evaluated using a repeated-measures analysis of covariance (ANCOVA) for each item. The ANCOVA model included terms for control variables (baseline measures of the NPS item [dependent variable], treatment center, age group, and sex), as well as factors for the fixed effects of treatment group and time of assessment (week 2, 4, or 6) and interaction terms of ''treatment by center'' and ''treatment by visit.'' The time effect associated with each ANCOVA determines whether the specific NPS item being examined is sensitive to the expected changes in pain experience associated with both treatment conditions, and the treatment effect indicates whether there is a significant impact of the opioid on the NPS item relative to the placebo. The significance levels of the treatment effect associated with each NPS descriptor provide an indication of the pattern of responses associated with opioid treatment in this sample.
In addition to examining changes in mean NPS item scores, we performed a responder analysis of the 10 NPS items. Participants were classified as being either a responder (completed with $33% reduction in the NPS item, pretreatment to 6 weeks) or nonresponder (discontinued or with ,33% reduction in the NPS item) to each of the 10 NPS items. Chi-square analyses were used to determine whether there was a difference in the frequency of responders between patients in the two treatment conditions. A 33% cutoff has been suggested as a reasonable standard for determining that a change in pain is meaningful from the patient's perspective, 21 based on previous research that has identified a range of possible cutoffs from about 28% to 40% (27.9%, 22 33%, 23, 24 35-40% 21 ).
Concerning the specific study hypotheses, we predicted significant treatment effects for sensitive, surface, itchy, intense, and unpleasant NPS items, with all items except for itchy predicted to show a greater decrease in the opioid condition than the placebo condition. Examination of the treatment effects for the remaining NPS items (sharp, hot, dull, cold, deep) will be used to help clarify the pattern of opioid responding assessed by the NPS. Table 1 presents the 10 NPS dimensions and their mean values at baseline. The mean values of baseline scores across the 10 pain sensations ranged from 3.8 to 7.9, with a median of 6.6. The three highest-scoring sensations were intense, unpleasant, and deep pain. Mean scores and corresponding standard deviations (SD) for each NPS item at weeks 2, 4, and 6 for the two treatment groups are also presented in Table 1 , with the results of the ANCOVA analyses of differences over time from pretreatment through posttreatment (time effect) and between treatment conditions across the assessment time points (overall treatment effect). Results at baseline and at 6 weeks are shown in Figure 1 .
RESULTS
A statistically significant (P , 0.05) decreasing trend (pretreatment to posttreatment) was observed in the overall mean values of seven of the NPS pain quality domains: intense, sharp, hot, dull, sensitive, unpleasant, and deep pain sensations. For five of these, the mean decreases were significantly larger in the opioid treatment group compared with the placebo group: intense (P = 0.003), sharp (P = 0.028), dull (P = 0.023), unpleasant (P = 0.018), and deep pain (P = 0.015) sensations. Although not statistically significant, larger mean reductions over time were observed in the opioid group compared with the placebo group for all remaining dimensions except for itchy pain. Two of these treatment effects approached statistical significance (hot, P = 0.054; surface, P = 0.083).
The responder analyses yielded similar results for three of the five NPS items found significant using ANCOVA analysis and one of the two NPS items found to approach statistical significance using the same analysis (Table 2 ). However, these analyses tended to be less sensitive to the effects of the opioid treatment than the ANCOVA analyses due to the loss of information associated with converting the ordinal response variables to dichotomous response variables. Significantly more participants responded to the opioid than to the placebo for the ratings of intense (P = 0.012), unpleasant (P = 0.019), deep (P = 0.039), and surface pain (P = 0.021). Although not statistically significant, more patients responded to the opioid than the placebo on the ratings of sharp, hot, dull, and cold pain, and these differences approached statistical significance for two of the ratings (hot, P = 0.086; sensitive, P = 0.093).
DISCUSSION
The present findings support the validity of the NPS items for detecting change in neuropathic pain with effective analgesia and provide preliminary evidence concerning the specific pain sensations affected by opioid treatment. The clinical implications of these findings concerning the use of the NPS in clinical trials on neuropathic pain and as a potential screening tool for physicians are discussed below.
The key question driving the current study was whether the multiple pain sensations associated with neuropathic pain and assessed by the NPS items are responsive to the effects of time and opioid treatment in a clinical trial of neuropathic pain that includes a treatment shown to affect neuropathic pain. The results of analyses examining mean changes indicated that 7 of the 10 NPS items showed expected changes in pain over time associated with participation in the clinical trial, with 5 of the NPS items showing greater decreases in pain among participants in the opioid treatment condition compared with participants in the placebo condition. The results of responder analyses indicated that more participants responded to the study analgesic than placebo on six NPS domains, with four of these showing statistical significance and two showing nonsignificant trends. The three NPS items that were most responsive to opioid treatment (relative to placebo) were two that assess global pain domains (intensity and unpleasantness) and the item that assesses deep pain.
Although the responder analyses were generally less sensitive than the ANCOVA analyses for detecting changes over time, they tended to replicate the ANCOVA findings. Significantly more patients were classified as responders in the opioid group compared with the placebo group for four of the NPS items (intense, unpleasant, deep, and surface pain), and there was a nonsignificant trend toward a greater chance of improvement in the opioid group than in the placebo group for hot and sensitive pain. In short, the findings support the validity of the NPS items for detecting change in neuropathic pain with treatment. Several factors, in addition to the efficacy of the treatment being studied, may influence the ability to detect treatment effects for an analgesic. These include the level of baseline pain at the start of a study, 25 with the ability to detect significant treatment differences greater when patients enter the study reporting relatively high levels of pain intensity compared with pain that is only mild to moderate in intensity. In the current study, the greatest impact of opioid treatment relative to placebo was observed for pain sensations with average baseline scores of at least 7.9 on a scale of 0 to 10. On the other hand, no significant effects, in either the ANCOVAs or the responder analyses, were found for the two NPS items whose baseline levels were below 5.0 (itchy and cold).
The hypothesis that opioid treatment produces a specific pattern of responses was supported by the findings that opioid treatment significantly reduced, relative to placebo, ratings of pain intensity, pain unpleasantness, and deep pain in both analyses, as well as ratings of sharp and dull pain in the ANCOVAs and surface pain in the responder analyses. Greater overall reductions were also seen in the opioid group relative to the placebo group for the hot and surface pain dimensions, although the differences for these descriptors were not statistically significant in the ANCOVAs (P = 0.054 and P = 0.083, respectively), and the reduction in hot pain was not statistically significant in the responder analysis (P = 0.086). To our knowledge, this study is the first to show a significant effect for opioid analgesia on specific pain sensations.
No statistically significant differences between opioid treatment and placebo were found for itchy, sensitive, or cold pain sensations in either analysis. These findings are consistent with previous results from a study of patients with a variety of neuropathic pain conditions, which showed that although administration of either IV lidocaine or phentolamine resulted in a decrease in 9 out of 10 neuropathic pain sensations measured by the NPS (all except itchy pain sensation), lidocaine was more effective than phentolamine in reducing unpleasant and deep pain sensations. 16 The results from this previous research using lidocaine and phentolamine and the current study involving CR oxycodone demonstrate and support the potential of the NPS items for separating therapeutic analgesic effects on identifiable pain sensations. Previous research showed the significant treatment effect of tramadol and oxycodone in reducing painful allodynia or sensitive pain sensations in patients with painful neuropathy 18 and in patients with postherpetic neuralgia. 20 It was therefore hypothesized that the opioid used in this study would have a greater effect than placebo on sensitive and surface pain sensations. However, due to several possible factors, this hypothesis was only partially supported in the current study. The only statistically significant effect to emerge was for surface pain in the responder analyses, and only nonsignificant trends were noted for sensitive pain in the responder analyses and for surface pain in the ANCOVAs. The data from this study suggest that painful diabetic neuropathy, although associated with high scores on several of the NPS dimensions, is not necessarily characterized by exceptionally high levels of sensitive pain. Hence, it is possible that the sensitive pain caused by diabetic neuropathy has a different etiology than the sensitive pain experienced by patients with postherpetic neuralgia. These differences could have contributed to the lack of large effects of opioid treatment on allodynia in the current study. Further, it is conceivable that population differences in the pretreatment levels of allodynia reported in patients with painful diabetic neuropathy compared with postherpetic neuralgia had some influence on the treatment effects seen in response to opioid treatment. Thus, greater treatment responses might have been observed had pretreatment levels of sensitive pain been higher in this study. Finally, it is not known whether greater treatment responses would have been observed if treatment had been extended beyond 6 weeks. Future research using patients with neuropathic pain associated with a variety of diagnoses and with relatively high levels of pretreatment pain sensitivity ratings, as well as a longer duration of treatment, would help clarify the possible reasons for the lack of a significant effect of opioid treatment on sensitive and surface pain seen in the current study.
The results of previous investigations, as well as the current study, indicating that different pain sensations are preferentially sensitive to different types of therapies suggest potential clinical implications for designing treatment regimens for patients. For example, the current findings suggest that opioid treatment (or at least CR oxycodone) may be more efficacious in patients with deep pain compared with patients with other pain sensations. However, this conclusion should be tempered by the fact that almost all (with the exception of itchy pain) of the sensations did decrease in response to CR oxycodone treatment compared with placebo, although not all treatment differences reached statistical significance in both the ANCOVA and responder analyses at 6 weeks.
In summary, the current results indicate that the NPS is sensitive to the effects of a treatment known to affect neuropathic pain. The findings also provide a preliminary assessment of the cluster of specific neuropathic pain dimensions assessed by the NPS in patients with painful diabetic neuropathy that are reduced by one opioid treatment (CR oxycodone). As more is understood regarding the pathologies that underlie neuropathic pain sensations, the use of measures such as the NPS may provide important clues concerning the mechanisms of different pain treatments.
